Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of MK-1167 with Diltiazem in Healthy Adults
NCT06703463Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of MK-1167 in Alzheimer's disease (AD) (2 arms), sponsored by Merck & Co. Primary endpoints: Number of participants who experience one or more adverse events (AEs) up to 99 days, Number of participants who discontinue study intervention due to an AE up to 85 days and 1 more. Started Oct 2023; status: completed.
02
Drugs
MK-1167
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06703463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06703463.